Neurochem’s Alzhemed for treatment of Alzheimer’s
July 18, 2004 by admin · Leave a Comment
On July 18, 2004, Neurochem Inc. released interim data pertaining to a Phase II open-label extension study of the effects of Alzhemed on cognitive function and global measure of performance in patients with mild-to-moderate Alzheimer’s Disease. According to Neurochem, the study showed that approximately 70% of the mild AD patients had stabilized or improved cognitive [...]
Namenda
February 6, 2004 by admin · Leave a Comment
In October of 2003, Forest Laboratories announced FDA approval of Namenda™ (memantine HCL) for moderate-to-severe Alzheimer’s disease. This new therapy is the first of a new class of drugs for Alzheimer’s disease known as NMDA antagonists. Namenda is thought to decrease the affinity of the NMDA receptor for a neurotransmitter known as glutamate, which plays [...]